GZERO SUMMIT Japan 2022 | Lovisa Afzelius
GZERO SUMMIT Japan 2022
This links to the home page
2021 Speakers
Lovisa  Afzelius
Lovisa Afzelius
Origination Partner, Flagship Pioneering
CONTACT INFORMATION
v-card icon V-Card
Lovisa Afzelius is an Origination Partner at Flagship Pioneering where she leads a team to invent and launch new therapeutic platforms. She is the Founding CEO and Director of Alltrna, pioneering tRNA as a new modality; the Co-founder, CEO and Director of FL77, focused on building variant-proof vaccines and therapeutics; and she leads numerous early stage Flagship companies. She is also a founding member of Flagship’s Pioneering Artificial Intelligence and Pre-emptive Medicine and Health Security initiatives.
 
A computational scientist by training with two decades of leadership experience, Lovisa has a passion for data-driven drug discovery, from early inception to clinical development across multiple therapeutic areas. Prior to joining Flagship, she was the SVP of Strategy & Operations at Cogen Immune Medicine, now known as Repertoire Immune Medicines. Lovisa has held or holds multiple leadership positions across emerging biotech companies as well as large pharma including CEO, co-founder, president, chairman of the board, and executive director.
 
Before joining the Flagship ecosystem, Lovisa built and led Pfizer’s systems immunology function and served as executive director of clinical programs. In this role, she launched several Phase II studies across autoimmune indications. As a member of the Inflammation & Immunology Research Unit leadership team, Lovisa managed the portfolio from early target discovery to Phase II clinical trials across all immunological assets. In addition, she served on Pfizer’s Worldwide R&D Data Strategy Committee.
 
In 2017, Lovisa co-founded Elsa.science, a digital health company in the rheumatoid arthritis space where she currently serves as chairman of the board. She also serves on the board of the Swedish New England Chamber of Commerce. Before her move to the US in 2013, Lovisa was CEO of BioChromix Pharma and led a successful strategic repositioning of the pipeline within neurodegenerative diseases.
 
She began her career at AstraZeneca as Project Director, Global In Vitro Metabolism Leader and Computational Chemist across cardiovascular, metabolic, and neurodegenerative diseases, spearheading the use of predictive modelling through chemometrics, quantum mechanics, neural networks, and protein modelling in the space of P450 drug metabolism and inhibition.
 
Lovisa has received numerous accolades for her work: she was included in the top 100 “most influential persons under age 40 in Sweden” by the business magazine, Affärsvärlden. In recognition of her “considerable personal contribution to moving the boundaries of science, and the application of that science, for the benefit of mankind,” she was recognized as a “scientist of tomorrow” at the European Federation of Pharmaceutical Industries and Associations’  30th anniversary.  Lovisa also received the Rosenön Award for best thesis of the year within the field of pharmacodynamics/pharmacokinetics in Sweden.